Anti-cyclic citrullinated antibodies: Complementary to IgM rheumatoid factor in the early diagnosis of rheumatoid arthritis

New Zealand Medical Journal

Volumn 117, Issue 1203, 2004, Pages

  Solanki, Kamal K ^a   Spellerberg, Myfanwy B ^b   Chapman, Peter T ^a   Moller, Peter ^a   O'Donnell, John L ^b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M; METHOTREXATE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; CITRULLINE; CYCLOPEPTIDE;

ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE DURATION; EARLY DIAGNOSIS; FREQUENCY ANALYSIS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; BLOOD; EVALUATION; IMMUNOLOGY;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CITRULLINE; HUMANS; IMMUNOGLOBULIN M; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 16644383021     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med. 1990;322:1277-89.
2. Scott D. The diagnosis and the prognosis of early arthritis: rationale for the new prognostic criteria. Arthritis Rheum. 2002;46:286-90.
3. Myllykangas-Luosujarvi RA, Aho K, Isomaki HA. Mortality in rheumatoid arthritis. Semin Arthritis Rheum. 1995;25:193-202.
4. Arnett FC, Edworthy SM, Bloch DA, et al The American Rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
5. Schellekens GA, de Jong BAW, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognised by rheumatoid arthritis-specific antibodies. J.Clin Invest. 1998;101:273-81.
6. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43:155-63.
7. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-CCP in patients with recent onset RA. Arthritis Rheum. 2000;43:1831-5.
8. Bozic B, Cucnik S, Ambrozic A, et al. Clinical sensitivity of antibodies against cyclic citrullinated peptide in patients with rheumatoid arthritis. Arthritis Res. 2001;3:(suppl A):P003.
9. Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early- a prediction model for persistent (erosive) arthritis. Arthritis Rheum. 2002;46:357-65.
10. Meyer O, Labarre C, Dougados M, et al. Anti-citrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis. 2003;62:120-6.
11. O'Dell J. Treating Rheumatoid Arthritis Early: a window of opportunity? Arthritis Rheum 2002;46:283-5.
12. Jansen AL, van der Horst-Bruinsma I, van Schaardenburg D, et al. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol. 2002;29:2074-6
13. Vencovsky J, Machacek S, Sedova L, et al. Autoantibodies can be prognostic markers of erosive disease in early rheumatoid arthritis. Ann Rheum Dis. 2003;62:427-30.